TEXT-EXTRACT 2 filename2.txt United States securities and exchange commission logo April 11, 2024 Jenny Robertson Chief Legal and Business Officer Lexeo Therapeutics, Inc. 345 Park Avenue South , Floor 6 New York , New York , 10010 Re: Lexeo Therapeutics, Inc. Registration Statement on Form S-1 Filed April 9, 2024 File No. 333-278566 Dear Jenny Robertson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Megan Baier